Melanotan I 10mg
Melanotan I (afamelanotide) is a linear analog of alpha-MSH with high MC1R selectivity. Unlike MT-II, it primarily stimulates melanogenesis without significant sexual or appetite effects. It is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP) and studied for photoprotection and vitiligo treatment.
Sequence
[Nle4, D-Phe7]-alpha-MSH (linear 13-amino acid peptide)
Market avg: $39.99 — save 37%
Volume pricing
Pay with USDC via Coinbase Commerce
Certificate of Analysis
Independently verified by Janoshik Analytical
Test ID
JAN-MT1-2026-001
Purity
99.3%
Method
HPLC-MS
Batch
MT1-2026-01A
Test Date
February 1, 2026
Identity
Confirmed
Storage Requirements
Lyophilized
Room temperature (15-25°C), protect from light
Reconstituted
2-8°C, use within 21 days
Linear melanocortin analog (afamelanotide). Reconstitute with bacteriostatic water.
Published Research
2 peer-reviewed studies
Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo
Lim HW, Grimes PE, Agbai O, et al. — JAMA Dermatology, 2015
Clinical trial of afamelanotide (MT-I) combined with phototherapy for vitiligo.
Afamelanotide for erythropoietic protoporphyria
Langendonk JG, Balwani M, Anderson KE, et al. — New England Journal of Medicine, 2015
Phase 3 trial leading to FDA approval for EPP treatment.
Related Products
Research use only. All products are sold strictly for in-vitro research purposes only. Not for human consumption. Information provided references published research literature. No medical claims are made or implied.